These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24468754)

  • 1. Male hypogonadism and skeletal health.
    Irwig MS
    Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):517-22. PubMed ID: 24468754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study.
    Szulc P; Claustrat B; Marchand F; Delmas PD
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5240-7. PubMed ID: 14602756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specific effect of testosterone on bone mineral density in male hypogonadism.
    Choi HR; Lim SK; Lee MS
    J Korean Med Sci; 1995 Dec; 10(6):431-5. PubMed ID: 8924228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone health in hypogonadal men.
    Irwig MS
    Curr Opin Urol; 2014 Nov; 24(6):608-13. PubMed ID: 25144148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bone and Men's Health. Androgen replacement therapy and bone metabolism].
    Ogawa S
    Clin Calcium; 2010 Feb; 20(2):251-7. PubMed ID: 20118518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption.
    Anderson FH; Francis RM; Peaston RT; Wastell HJ
    J Bone Miner Res; 1997 Mar; 12(3):472-8. PubMed ID: 9076591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
    Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
    Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden.
    Mellström D; Johnell O; Ljunggren O; Eriksson AL; Lorentzon M; Mallmin H; Holmberg A; Redlund-Johnell I; Orwoll E; Ohlsson C
    J Bone Miner Res; 2006 Apr; 21(4):529-35. PubMed ID: 16598372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
    Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
    Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of testosterone replacement therapy on bone in hypogonadal men with Klinefelter Syndrome.
    Tahani N; Nieddu L; Prossomariti G; Spaziani M; Granato S; Carlomagno F; Anzuini A; Lenzi A; Radicioni AF; Romagnoli E
    Endocrine; 2018 Aug; 61(2):327-335. PubMed ID: 29696556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone, bone and osteoporosis.
    Tuck S; Francis R
    Front Horm Res; 2009; 37():123-132. PubMed ID: 19011293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen replacement in aging men.
    Francis RM
    Calcif Tissue Int; 2001 Oct; 69(4):235-8. PubMed ID: 11730258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.
    Yaturu S; DjeDjos S; Alferos G; Deprisco C
    Prostate Cancer Prostatic Dis; 2006; 9(1):35-8. PubMed ID: 16276350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoporosis in older men: recent advances in pathophysiology and treatment.
    Laurent M; Gielen E; Claessens F; Boonen S; Vanderschueren D
    Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):527-39. PubMed ID: 24054929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.